TY  - CHAP
M1  - Book, Section
TI  - Pathology of Lymphomas
A1  - Gascoyne, Randy D.
A1  - Skinnider, Brian F.
A2  - Press, Oliver W.
A2  - Lichtman, Marshall A.
A2  - Leonard, John P.
Y1  - 2017
N1  - 
T2  - Williams Hematology Malignant Lymphoid Diseases
AB  - SUMMARYThe  World  Health  Organization  (WHO)  classification  of  lymphoid  neoplasms  has  gained  worldwide  acceptance  by  both  pathologists  and  oncologists.  As  further  advances  in  the  classification  of  lymphoma  are  agreed  upon,  the  WHO  provides  an  updated  version  of  its  classification.  The  most  recent  modification  was  published  in  2016.  It  provides  a  list  of  distinct  lymphocytic  neoplasms  that  are  defined  by  a  combination  of  morphologic,  immunophenotypic,  genetic,  and  clinical  features  and  correlates  each  disease  with  a  cell  of  origin  in  the  lymphopoietic  hierarchy.  Because  the  classification  of  lymphomas  requires  the  integration  of  such  diverse  information,  the  diagnosis  of  specific  lymphomas  has  become  more  complex  compared  to  other  malignancies.  As  a  result,  several  ancillary  studies  have  become  essential  in  the  diagnosis  of  a  specific  pathological  type  of  lymphoma,  requiring  special  handling  of  biopsy  material  when  a  diagnosis  of  lymphoma  is  suspected.  The  WHO  classification  identifies  three  major  categories  of  lymphoid  malignancies:  B-cell  neoplasms,  T-  and  natural-killer  (NK)  cell  neoplasms,  and  Hodgkin  lymphoma.  Two  major  categories  are  identified  within  the  B-cell  and  T-/NK-cell  neoplasms:  precursor  neoplasms  and  peripheral  or  mature  neoplasms.  Unlike  previous  lymphoma  classifications,  the  WHO  classification  does  not  group  different  lymphomas  by  clinical  outcome  or  histologic  grade.  It  recognizes  that  each  disease  has  distinctive  clinical  features  and  response  to  treatment  and  may  have  a  spectrum  of  rate  of  clinical  progression  that  may  correlate  with  histologic  grade  or  gene  expression  patterns.  New  approaches  for  classifying  lymphoma  include  the  study  of  gene  expression  profiling  by  complementary  DNA  microarray  technology,  which  provides  additional  insights  into  the  subclassification  of  diseases  such  as  diffuse  large  B-cell  lymphoma  and  chronic  lymphocytic  leukemia.  Proteomic  approaches  will  add  further  texture  to  the  molecular  taxonomy  of  lymphoma  classification.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/23
UR  - hemonc.mhmedical.com/content.aspx?aid=1148368305
ER  -